- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06492538
Biometric Changes After Intervention of Anterior Chamber Angle : an Observational Study
December 4, 2025 updated by: Xinbo Gao, Zhongshan Ophthalmic Center, Sun Yat-sen University
The drainage angle in the anterior chamber of the eye mediates the outflow of aqueous humor, and pathological changes here can lead to high intraocular pressure and glaucoma.
Minimally invasive glaucoma surgery, particularly angle surgery, has advanced recently, allowing clear visualization of angle structures like the trabecular meshwork and Schlemm's canal using surgical goniolens.
Techniques for angle intervention include widening the angle, reopening closed angles, and rebuilding outflow pathways using methods such as laser peripheral iridotomy, Argon laser peripheral iridoplasty, and mechanical separation of adhered tissues.
Our research team plans to conduct imaging studies to track the healing of angle tissues post-surgery, aiming to support innovation and standardization of minimally invasive angle surgery.
Study Overview
Status
Recruiting
Conditions
Intervention / Treatment
Detailed Description
Pathological elevated intraocular pressure is one of the most important disease characteristics of glaucoma.
Blockage of aqueous humor outflow within the eye is the primary cause of high intraocular pressure.
The drainage angle in the anterior chamber of the eye mediates the outflow of aqueous humor.
Pathological changes in this area can lead to the development of high intraocular pressure and glaucoma, such as primary angle closure glaucoma (PACG) caused by angle closure.
Minimally invasive glaucoma surgery has rapidly developed in recent years, with angle surgery being a major branch.
With the use of surgical goniolens, structures within the angle, such as trabecular meshwork and Schlemm's canal, can be visualized clearly during surgery.
Methods for angle intervention include but not limit ed to widening the peripheral anterior chamber angle, reopening adhered or appositionally closed angles, and rebuilt outflow pathways by incising diseased areas to increase aqueous humor outflow.
Techniques include laser peripheral iridotomy (LPI) to relieve pupillary block and deepen the peripheral anterior chamber, Argon laser peripheral iridoplasty (ALPIP) to stimulate iris contraction and widen the angle, and mechanical separation of adhered angle tissues using instruments like goniosynechialysis hooks or iris repositors.
Surgical incision using instruments such as Microhook, trabeculectomy hooks, or cannulas can be performed to remove the diseased inner wall of Schlemm's canal and the diseased trabecular meshwork either partially or circumferentially.
However, the healing and outcomes of angle tissues following invasive angle interventions, and their impact on surgical outcomes, remain unclear.
Therefore, our research team proposes to conduct imaging observation studies to track, observe, and quantify the status of the angle, exploring the healing process of angle tissues.
This aims to provide theoretical support for the innovation and standardization of minimally invasive angle surgery.
Study Type
Observational
Enrollment (Estimated)
300
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Xinbo Gao, MD
- Phone Number: +8618319579657
- Email: gaoxb@mail.sysu.edu.cn
Study Locations
-
-
Guangdong
-
Guangzhou, Guangdong, China, 51006dddddd0
- Recruiting
- Zhongshan Ophthalmic Center
-
Contact:
- Xinbo Gao, MD
- Phone Number: +8618319579657
- Email: gaoxb@mail.sysu.edu.cn
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
N/A
Sampling Method
Non-Probability Sample
Study Population
Patients diagnosed with glaucoma typically present with: IOP > 21 mmHg with or without the use of ocular hypotensive medications; (3) with obvious glaucomatous optic neuropathy [cup-to-disc (C/D) ratio ≥ 0.7, C/D ratio asymmetry > 0.2, or rim width at the superotemporal and inferotemporal < 0.1 vertical diameter of the optic disc], and glaucomatous visual field defects, such as nasal step, arcuate scotoma, and paracentral scotoma;
Description
Inclusion Criteria:
- Glaucoma patients eligible for standalone or combined angle intervention surgeries, such as LPI, LPIP, goniosynechialysis, trabeculotomy alone or combined with surgical iridectomy or phacoemulsification and intraocular lens implantation;
- Patients capable of undergoing preoperative examinations including CASIA2-OCT (anterior segment OCT), UBM, slit-lamp gonioscopy, IOL Master (or other optical biometry);
- Patients willing to participate in this study, signing informed consent, and agreeing to follow-up according to the study protocol.
Exclusion Criteria:
- Patients with severe ocular conditions such as corneal infection, ulcer, trauma, ocular tumors, retinal vascular occlusion, and retinal detachment;
- Those with various types of eye diseases that affect ocular parameter acquisition or interfere with visual field examination;
- Long-term local or systemic use of glucocorticoids;
- Patients with severe systemic diseases;
- Pregnant or lactating women;
- Unable to complete 12-month postoperative follow-up.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
|---|---|
|
laser peripheral iridotomy/iridoplasty group
based on angle closure mechanism, procedures were chosen LPI alone or combined with ALPIp. LPI: laser peripheral iridotomy; ALPIp: argon laser peripheral iridoplasty. |
procedures include laser peripheral iridotomy (LPI) to relieve pupillary tissue and deepen peripheral anterior chamber depth, Argon laser peripheral iridoplasty (ALPIp) to stimulate iris contraction and widen the angle, and mechanical separation of adhered angle tissues using instruments like goniosynechialysis hooks or iris repositor.
Ab interno goniotomy using instruments like retina hooks, trabeculectomy hooks, or cannulas are used to incise trabecular meshwork and Schlemm's canal walls to enhance aqueous humor outflow.
|
|
peripheral iridectomy based surgery combo
SPI combined with GSL or GSL+GT SPI: surgical peripheral iridectomy GSL:goniosynechialysis GT: goniotomy GSL and GT are both guided by surgical goniolens
|
procedures include laser peripheral iridotomy (LPI) to relieve pupillary tissue and deepen peripheral anterior chamber depth, Argon laser peripheral iridoplasty (ALPIp) to stimulate iris contraction and widen the angle, and mechanical separation of adhered angle tissues using instruments like goniosynechialysis hooks or iris repositor.
Ab interno goniotomy using instruments like retina hooks, trabeculectomy hooks, or cannulas are used to incise trabecular meshwork and Schlemm's canal walls to enhance aqueous humor outflow.
|
|
phacoemulsification and intraocular lens implantation based surgery combo
PEI: phacoemulsification and intraocular lens implantation surgery combo includes GSL alone or GSL+GT.
|
procedures include laser peripheral iridotomy (LPI) to relieve pupillary tissue and deepen peripheral anterior chamber depth, Argon laser peripheral iridoplasty (ALPIp) to stimulate iris contraction and widen the angle, and mechanical separation of adhered angle tissues using instruments like goniosynechialysis hooks or iris repositor.
Ab interno goniotomy using instruments like retina hooks, trabeculectomy hooks, or cannulas are used to incise trabecular meshwork and Schlemm's canal walls to enhance aqueous humor outflow.
|
|
ab interno goniotomy
GT was performed in the nasal-inferior quadrant or nasal quadrant because the collector channels were mainly concentrated in the nasal quadrant, by inserting the tip of a microblade (TMH; Tanito Microhook, Inami & Co., Ltd., Tokyo, Japan) into Schlemm's canal, and then the inner wall of Schlemm's canal and trabecular meshwork was incised over 120°
|
procedures include laser peripheral iridotomy (LPI) to relieve pupillary tissue and deepen peripheral anterior chamber depth, Argon laser peripheral iridoplasty (ALPIp) to stimulate iris contraction and widen the angle, and mechanical separation of adhered angle tissues using instruments like goniosynechialysis hooks or iris repositor.
Ab interno goniotomy using instruments like retina hooks, trabeculectomy hooks, or cannulas are used to incise trabecular meshwork and Schlemm's canal walls to enhance aqueous humor outflow.
|
|
Schlemm canaloplasty
performed in the nasal quadrant by the collector channels were mainly concentrated in the nasal quadrant, by inserting the tip of a microblade (TMH; Tanito Microhook, Inami & Co., Ltd., Tokyo, Japan) into Schlemm's canal, and then the inner wall of Schlemm's canal and trabecular meshwork was incised over 120°
|
procedures include laser peripheral iridotomy (LPI) to relieve pupillary tissue and deepen peripheral anterior chamber depth, Argon laser peripheral iridoplasty (ALPIp) to stimulate iris contraction and widen the angle, and mechanical separation of adhered angle tissues using instruments like goniosynechialysis hooks or iris repositor.
Ab interno goniotomy using instruments like retina hooks, trabeculectomy hooks, or cannulas are used to incise trabecular meshwork and Schlemm's canal walls to enhance aqueous humor outflow.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Changes in biological parameters of the anterior chamber angle
Time Frame: 12 months
|
Biological parameter changes in the anterior chamber following angle intervention surgery will be measured using Casia2-OCT
|
12 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
success rate of angle intervention surgeries
Time Frame: 12 months
|
complete success was defined as postoperative IOP within the range of 6-18 mmHg, and a reduction of 20% from baseline without loss of light perception, additional ocular hypotensive medication, and reoperation.
The definition of qualified success was similar to that of complete success, except for the need for ocular hypotensive medications.
Postoperative ocular hypotensive medications were adjusted according to the IOP at each visit.
|
12 months
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
safety of angle intervention surgeries
Time Frame: 1 months
|
The main observation includes recording intraoperative and postoperative complications, including hyphema, choroidal detachment, cyclodialysis, persistent hypotony, corneal decompensation, and intraocular inflammation.
|
1 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Investigators
- Principal Investigator: Xinbo Gao, MD, State Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Center, Sun Yat-sen University
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
December 1, 2023
Primary Completion (Estimated)
December 30, 2025
Study Completion (Estimated)
December 30, 2025
Study Registration Dates
First Submitted
July 1, 2024
First Submitted That Met QC Criteria
July 1, 2024
First Posted (Actual)
July 9, 2024
Study Record Updates
Last Update Posted (Actual)
December 12, 2025
Last Update Submitted That Met QC Criteria
December 4, 2025
Last Verified
October 1, 2025
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2023KYPJ304
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.